Benjamin Heyman, MD

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma. 

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.